Impact of IntraVascular UltraSound Guidance on Outcomes of Xience Prime Stents in Long Lesions (IVUS-XPL Study)

Exclusion Criteria

• •Acute ST elevation myocardial infarction within 48 hours
• •Contraindication to anti-platelet agents \& bleeding history within prior 3 months
• •Known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Zotarolimus or other -limus group
• •Prior history of the following presentations
• •* Cerebral vascular accident (not including transient ischemic attack)
• •* Peripheral artery occlusive diseases
• •* Thromboembolic disease
• •* Stent thrombosis
• •Age \> 80 years old
• •Severe hepatic dysfunction (3 times normal reference values)
• •Significant renal dysfunction (Serum creatinine \> 2.0 mg/dl)
• •Significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis
• •Cardiogenic shock
• •LVEF \< 40%
• •Pregnant women or women with potential childbearing
• •Life expectancy \< 1 year
• •Left main disease requiring PCI
• •Bifurcation lesion with 2-stent technique
• •Chronic total occlusion
• •Presence of previously implanted DES within 6-month
• •In-stent restenosis lesion